A Double-blind, Placebo-Controlled, Parallel-group, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of BMS-823778 in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Either Diet and Exercise Alone or on a Background of Metformin.
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2015
At a glance
- Drugs BMS 823778 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 22 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jan 2011 Planned End Date changed from 1 Dec 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
- 06 Jan 2011 Planned End Date changed from 1 Jan 2011 to 1 Dec 2010 as reported by ClinicalTrials.gov.